Skip to main content

Specialty Pharmacy

  • Walgreens to focus on importance of HIV testing, early treatment on World AIDS Day

    DEERFIELD, Ill. — On World AIDS Day, Dec. 1, Walgreens will encourage communities to focus on the importance of HIV testing and early treatment, both services addressed through its more than 700 HIV-specialized pharmacies coast to coast, the company announced Wednesday. 

  • Novo Nordisk app designed to help hemophilia patients, families

    PRINCETON, N.J. — Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

    HemaGo — available for iPhone, iPad and Android devices — is designed to track hemophilia treatment, bleeding episodes and life events, helping people with the condition and their caregivers monitor the details of treatment, including medications, dosing, bleeding information and the disease's effects on life events.

  • Traditional drug spending falls, specialty spending rises, ESI report finds

    ST. LOUIS — Price inflation for the most commonly used branded drugs has been more than six times that of overall inflation for consumer goods since September 2011, according to a new report by pharmacy benefit manager Express Scripts.

  • Medication nonadherence costs drug makers $188 billion per year in U.S., report finds

    NORWALK, Conn. — When it comes to medication non-adherence, the most oft-cited statistic illustrating its effect on the healthcare system is the New England Healthcare Institute's estimate that it costs the healthcare system $290 billion per year. But a new report shows how much drug makers lose as well.

  • Fred's looks to grow through Diplomat Specialty partnership and Drug and Dollar concept pharmacy

    MEMPHIS, Tenn. — Any trickle-down of an improving economy hasn't trickled down to Fred's consumer base, Bruce Efird, Fred's CEO, told analysts Tuesday morning in discussing the discounter's third-quarter results. "During the third quarter we continue to see generally weak economic conditions throughout the Southeast which are clearly weighing heavily on our customers and influencing how they shop for their basic needs," he said. "It's more evident that things are not getting better for our core customers." 

  • Pfizer, Cystic Fibrosis Foundation Therapeutics partner in drug-discovery initiative

    BETHESDA, Md. — The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

  • FDA approves GSK drug for hepatitis C patients with low platelet counts

    LONDON — The Food and Drug Administration has approved a drug for a condition that can complicate treatment for hepatitis C.

    GlaxoSmithKline said Monday that the FDA had approved Promacta (eltrombopag) for treating low blood-platelet counts, also known as thrombocytopenia, to allow patients with hepatitis C to undergo and maintain interferon-based therapy. The drug already had FDA approval to treat chronic immune thrombocytopenia. 

  • Shire launches rare-disease research project

    LEXINGTON, Mass. — Drug maker Shire has started a research program focused on rare diseases and their effects on patients and healthcare professionals, the company said Monday.

    Shire announced the launch of the Shire Rare Disease Impact Report, which includes surveys of patients, caregivers, physicians, payers and others in the United States and United Kingdom, with results expected in the first half of 2013.

X
This ad will auto-close in 10 seconds